COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial;

NCT04534725 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

441

Enrollment

OTHER

Sponsor class

Conditions

Cancer
Covid19
Respiratory Viral Infection

Interventions

DRUG: Interferon alfa
DRUG: Selinexor
DRUG: Lenzilumab

Sponsor

Peter MacCallum Cancer Centre, Australia